TO the editorial office
UPDATED 18:45 PT – Friday, November 20, 2020
The FDA has issued an emergency authorization for a combination of coronavirus drugs to treat moderate to severe patients.
FDA Commissioner Dr. Stephen M. Hahn said the action demonstrates the agency’s continued efforts to provide timely treatment for coronavirus.
On Thursday, the FDA approved the combination of remdesevir and the rheumatoid arthritis drug baricitinib. This happened after studies found that the drug combination shortened the recovery time of COVID-19 to about a week.
To date, 289 tests have been approved by the FDA under EUAs; they include 224 molecular assays, 58 antibody assays, and 7 antigen assays.
– US FDA (@US_FDA) November 21, 2020
According to a double-blind study, the combination also increased the chances of survival by 35% compared with patients taking remdezivir alone.
The FDA has authorized the emergency use of the arthritis drug baricitinib to be used in combination with remdezivir for the treatment of hospitalized adults and children with suspected or confirmed COVID-19. https://t.co/GVSGz9mdRx pic.twitter.com/esKvNvIg8x
– WebMD (@WebMD) November 20, 2020